PE20230845A1 - Pirimidinas cicloalquiladas como inhibidores de la ferroportina - Google Patents
Pirimidinas cicloalquiladas como inhibidores de la ferroportinaInfo
- Publication number
- PE20230845A1 PE20230845A1 PE2022002516A PE2022002516A PE20230845A1 PE 20230845 A1 PE20230845 A1 PE 20230845A1 PE 2022002516 A PE2022002516 A PE 2022002516A PE 2022002516 A PE2022002516 A PE 2022002516A PE 20230845 A1 PE20230845 A1 PE 20230845A1
- Authority
- PE
- Peru
- Prior art keywords
- iron
- alkyl
- compounds
- pyridin
- ferroportin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Esta referido a compuestos de Formula I', en donde: Rx es halogeno, alquilo, alcoxi, hidroxi, oxo o ciano; R3 es H, alquilo opcionalmente deuterado, hidroxi-alquilo, halo-alquilo, ciclopropilo o fenilo; R4 es (heteroarilo monociclico o biciclico fusionado de 5 a 10 miembros)-alquilo C1-C3, (heterociclilo monociclico de 6 o 7 miembros)-alquilo C1-C3, entre otras opciones; Z es N o CH; Anillo B es como se indica a continuacion en la figura; m es 0, 1 o 2; y, p es 1 o 2. Entre los compuestos preferidos tenemos los siguientes: 7-metoxi-3-[2-(piridin-2-il)- 5H,6H,7H-ciclopenta[d]pirimidin4-il]-2,3,4,5-tetrahidro-1H-3- benzazepina; N-(2-fluorofenil)-2-{[2-(piridin-2- il)-5H,6H,7Hciclopenta[d]pirimidin-4- il]amino}acetamida; (2R)-N-tert-butil-3-metil-2-{metil[2-(piridin-2-il)-5H,6H,7Hciclopenta[d]pirimidin-4-il]amino}butanamida; entre otros. Estos compuestos son inhibidores de ferroportina, la cual es la proteina de transporte de hierro responsable de la captacion del hierro liberado a traves del intestino y su transferencia a la circulacion sanguinea, donde finalmente el hierro se entrega a los tejidos y organos apropiados. La inactivacion o inhibicion de la ferroportina reduce o evita la exportacion del hierro, reduciendo asi la absorcion de hierro en el intestino y, la cantidad de hierro en el cuerpo. Estos compuestos se emplean en el tratamiento de enfermedades causadas por falta de hepcidina o trastornos del metabolismo del hierro, en particular estados de sobrecarga de hierro, como talasemia, anemia de celulas falciformes y hemocromatosis, y tambien lesiones renales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063016891P | 2020-04-28 | 2020-04-28 | |
US202063127774P | 2020-12-18 | 2020-12-18 | |
PCT/US2021/029574 WO2021222363A1 (en) | 2020-04-28 | 2021-04-28 | Cycloalkyl pyrimidines as ferroportin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230845A1 true PE20230845A1 (es) | 2023-05-23 |
Family
ID=75954294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002516A PE20230845A1 (es) | 2020-04-28 | 2021-04-28 | Pirimidinas cicloalquiladas como inhibidores de la ferroportina |
Country Status (18)
Country | Link |
---|---|
US (2) | US11746100B2 (es) |
EP (1) | EP4143178A1 (es) |
JP (1) | JP2023524033A (es) |
KR (1) | KR20230007441A (es) |
CN (1) | CN115836063A (es) |
AU (1) | AU2021263818A1 (es) |
BR (1) | BR112022021806A2 (es) |
CA (1) | CA3180661A1 (es) |
CL (1) | CL2022003013A1 (es) |
CO (1) | CO2022015395A2 (es) |
CR (1) | CR20220556A (es) |
DO (1) | DOP2022000236A (es) |
EC (1) | ECSP22084239A (es) |
IL (1) | IL297624A (es) |
MX (1) | MX2022013518A (es) |
PE (1) | PE20230845A1 (es) |
TW (1) | TW202206421A (es) |
WO (1) | WO2021222363A1 (es) |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
CN1894222A (zh) * | 2003-08-05 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道抑制剂的稠合嘧啶化合物 |
US9328140B2 (en) | 2008-12-05 | 2016-05-03 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
AU2009322260B2 (en) | 2008-12-05 | 2013-09-12 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
AR077999A1 (es) * | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
EP2968443B1 (en) | 2013-03-15 | 2021-09-29 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
US9981012B2 (en) | 2013-09-20 | 2018-05-29 | University Of Virginia Patent Foundation | Compositions and methods for protecting the kidney from ischemia reperfusion injury |
US9315545B2 (en) | 2014-04-07 | 2016-04-19 | Merganser Biotech, Inc. | Hepcidin mimetic peptides and uses thereof |
WO2015200916A2 (en) | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
JP2018508466A (ja) | 2014-12-29 | 2018-03-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | S−アルキル化ヘプシジンペプチドならびにその作製及び使用方法 |
JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
US11286243B2 (en) | 2018-12-13 | 2022-03-29 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
-
2021
- 2021-04-28 WO PCT/US2021/029574 patent/WO2021222363A1/en active Application Filing
- 2021-04-28 MX MX2022013518A patent/MX2022013518A/es unknown
- 2021-04-28 CR CR20220556A patent/CR20220556A/es unknown
- 2021-04-28 US US17/242,731 patent/US11746100B2/en active Active
- 2021-04-28 JP JP2022566040A patent/JP2023524033A/ja active Pending
- 2021-04-28 KR KR1020227041423A patent/KR20230007441A/ko active Search and Examination
- 2021-04-28 BR BR112022021806A patent/BR112022021806A2/pt unknown
- 2021-04-28 AU AU2021263818A patent/AU2021263818A1/en active Pending
- 2021-04-28 CN CN202180047289.0A patent/CN115836063A/zh active Pending
- 2021-04-28 EP EP21726289.8A patent/EP4143178A1/en active Pending
- 2021-04-28 CA CA3180661A patent/CA3180661A1/en active Pending
- 2021-04-28 PE PE2022002516A patent/PE20230845A1/es unknown
- 2021-04-28 TW TW110115440A patent/TW202206421A/zh unknown
- 2021-04-28 IL IL297624A patent/IL297624A/en unknown
-
2022
- 2022-10-28 DO DO2022000236A patent/DOP2022000236A/es unknown
- 2022-10-28 CL CL2022003013A patent/CL2022003013A1/es unknown
- 2022-10-28 CO CONC2022/0015395A patent/CO2022015395A2/es unknown
- 2022-10-28 EC ECSENADI202284239A patent/ECSP22084239A/es unknown
-
2023
- 2023-06-15 US US18/335,480 patent/US20240140932A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP22084239A (es) | 2023-01-31 |
DOP2022000236A (es) | 2023-01-31 |
IL297624A (en) | 2022-12-01 |
CO2022015395A2 (es) | 2022-11-08 |
TW202206421A (zh) | 2022-02-16 |
CL2022003013A1 (es) | 2023-06-30 |
US20220396562A1 (en) | 2022-12-15 |
EP4143178A1 (en) | 2023-03-08 |
CR20220556A (es) | 2022-12-15 |
JP2023524033A (ja) | 2023-06-08 |
CN115836063A (zh) | 2023-03-21 |
US11746100B2 (en) | 2023-09-05 |
BR112022021806A2 (pt) | 2022-12-13 |
MX2022013518A (es) | 2023-02-01 |
KR20230007441A (ko) | 2023-01-12 |
AU2021263818A1 (en) | 2022-11-03 |
WO2021222363A1 (en) | 2021-11-04 |
US20240140932A1 (en) | 2024-05-02 |
CA3180661A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10112932B2 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
CN105051041A (zh) | 杂环谷氨酰胺酶抑制剂 | |
EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
RU2017145026A (ru) | Соединение, ингибирующее brk | |
WO2018005533A1 (en) | Antiproliferative pyrimidine-based compounds | |
MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
PL1720825T3 (pl) | Pochodne kwasu antranilowego, sposoby ich wytwarzania oraz zastosowanie jako inhibitorów DHOH | |
WO2014130856A2 (en) | Treatment of skeletal-related disorders | |
AU2010286569A1 (en) | Compounds and compositions as protein kinase inhibitors | |
GEP20115147B (en) | Pyrimidine derivatives used as pi-3 kinase inhibitors | |
IS6022A (is) | Kínazólínafleiður sem æðamyndunarlatar | |
MX2012010655A (es) | Compuestos espirociclicos y su uso como agentes terapeuticos y sondas de diagnostico. | |
AR055321A1 (es) | Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende | |
CN104513252A (zh) | 取代脲衍生物及其在药物中的应用 | |
HRP20110244T1 (hr) | Postupak liječenja raka | |
US20210221805A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
JP2013127001A (ja) | ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および17−aagのようなhsp90阻害剤を含む組合せ剤 | |
PE20232046A1 (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas | |
CN104513257A (zh) | 取代脲衍生物及其在药物中的应用 | |
CN104130265B (zh) | 一种含有螺环或桥环的嘧啶类化合物 | |
CN104418842A (zh) | 取代的吲哚化合物及其使用方法和用途 | |
KR20210100623A (ko) | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 | |
PE20230845A1 (es) | Pirimidinas cicloalquiladas como inhibidores de la ferroportina |